267 related articles for article (PubMed ID: 38474418)
21. Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorders.
Savitz J
Curr Top Behav Neurosci; 2017; 31():249-267. PubMed ID: 27221627
[TBL] [Abstract][Full Text] [Related]
22. Recent advances in clinical trials targeting the kynurenine pathway.
Pires AS; Sundaram G; Heng B; Krishnamurthy S; Brew BJ; Guillemin GJ
Pharmacol Ther; 2022 Aug; 236():108055. PubMed ID: 34929198
[TBL] [Abstract][Full Text] [Related]
23. The kynurenine pathway in chronic diseases: a compensatory mechanism or a driving force?
Joisten N; Ruas JL; Braidy N; Guillemin GJ; Zimmer P
Trends Mol Med; 2021 Oct; 27(10):946-954. PubMed ID: 34373202
[TBL] [Abstract][Full Text] [Related]
24. Metabolism of L-tryptophan to kynurenate and quinolinate in the central nervous system: effects of 6-chlorotryptophan and 4-chloro-3-hydroxyanthranilate.
Naritsin DB; Saito K; Markey SP; Chen CY; Heyes MP
J Neurochem; 1995 Nov; 65(5):2217-26. PubMed ID: 7595510
[TBL] [Abstract][Full Text] [Related]
25. Quinolinate as a Marker for Kynurenine Metabolite Formation and the Unresolved Question of NAD
Moffett JR; Arun P; Puthillathu N; Vengilote R; Ives JA; Badawy AA; Namboodiri AM
Front Immunol; 2020; 11():31. PubMed ID: 32153556
[TBL] [Abstract][Full Text] [Related]
26. Tryptophan, kynurenine, and kynurenine metabolites: Relationship to lifetime aggression and inflammatory markers in human subjects.
Coccaro EF; Lee R; Fanning JR; Fuchs D; Goiny M; Erhardt S; Christensen K; Brundin L; Coussons-Read M
Psychoneuroendocrinology; 2016 Sep; 71():189-96. PubMed ID: 27318828
[TBL] [Abstract][Full Text] [Related]
27. Changing the face of kynurenines and neurotoxicity: therapeutic considerations.
Bohár Z; Toldi J; Fülöp F; Vécsei L
Int J Mol Sci; 2015 Apr; 16(5):9772-93. PubMed ID: 25938971
[TBL] [Abstract][Full Text] [Related]
28. The Trace Kynurenine, Cinnabarinic Acid, Displays Potent Antipsychotic-Like Activity in Mice and Its Levels Are Reduced in the Prefrontal Cortex of Individuals Affected by Schizophrenia.
Ulivieri M; Wierońska JM; Lionetto L; Martinello K; Cieslik P; Chocyk A; Curto M; Di Menna L; Iacovelli L; Traficante A; Liberatore F; Mascio G; Antenucci N; Giannino G; Vergassola M; Pittaluga A; Bruno V; Battaglia G; Fucile S; Simmaco M; Nicoletti F; Pilc A; Fazio F
Schizophr Bull; 2020 Dec; 46(6):1471-1481. PubMed ID: 32506121
[TBL] [Abstract][Full Text] [Related]
29. 4-Chloro-3-hydroxyanthranilate, 6-chlorotryptophan and norharmane attenuate quinolinic acid formation by interferon-gamma-stimulated monocytes (THP-1 cells).
Saito K; Chen CY; Masana M; Crowley JS; Markey SP; Heyes MP
Biochem J; 1993 Apr; 291 ( Pt 1)(Pt 1):11-4. PubMed ID: 8471029
[TBL] [Abstract][Full Text] [Related]
30. The Role of Tryptophan Dysmetabolism and Quinolinic Acid in Depressive and Neurodegenerative Diseases.
Hestad K; Alexander J; Rootwelt H; Aaseth JO
Biomolecules; 2022 Jul; 12(7):. PubMed ID: 35883554
[TBL] [Abstract][Full Text] [Related]
31. The role of tryptophan metabolism in postpartum depression.
Duan KM; Ma JH; Wang SY; Huang Z; Zhou Y; Yu H
Metab Brain Dis; 2018 Jun; 33(3):647-660. PubMed ID: 29307018
[TBL] [Abstract][Full Text] [Related]
32. Relationship of tryptophan metabolites with the type and severity of multiple sclerosis.
Isık SMT; Onmaz DE; Ekmekci AH; Ozturk S; Unlu A; Abusoglu S
Mult Scler Relat Disord; 2023 Sep; 77():104898. PubMed ID: 37481818
[TBL] [Abstract][Full Text] [Related]
33. Tryptophan, adenosine, neurodegeneration and neuroprotection.
Stone TW; Forrest CM; Mackay GM; Stoy N; Darlington LG
Metab Brain Dis; 2007 Dec; 22(3-4):337-52. PubMed ID: 17712616
[TBL] [Abstract][Full Text] [Related]
34. Alzheimer's Disease: Recent Concepts on the Relation of Mitochondrial Disturbances, Excitotoxicity, Neuroinflammation, and Kynurenines.
Zádori D; Veres G; Szalárdy L; Klivényi P; Vécsei L
J Alzheimers Dis; 2018; 62(2):523-547. PubMed ID: 29480191
[TBL] [Abstract][Full Text] [Related]
35. [Kynurenines in pathogenesis of endogenous psychiatric disorders].
Shilov IuE; Bezrukov MV
Vestn Ross Akad Med Nauk; 2013; (1):35-41. PubMed ID: 23805637
[TBL] [Abstract][Full Text] [Related]
36. Dynamic changes in kynurenine pathway metabolites in multiple sclerosis: A systematic review.
Fathi M; Vakili K; Yaghoobpoor S; Tavasol A; Jazi K; Mohamadkhani A; Klegeris A; McElhinney A; Mafi Z; Hajiesmaeili M; Sayehmiri F
Front Immunol; 2022; 13():1013784. PubMed ID: 36426364
[TBL] [Abstract][Full Text] [Related]
37. Maternal genotype determines kynurenic acid levels in the fetal brain: Implications for the pathophysiology of schizophrenia.
Beggiato S; Notarangelo FM; Sathyasaikumar KV; Giorgini F; Schwarcz R
J Psychopharmacol; 2018 Nov; 32(11):1223-1232. PubMed ID: 30354938
[TBL] [Abstract][Full Text] [Related]
38. Suicidality and Activation of the Kynurenine Pathway of Tryptophan Metabolism.
Bryleva EY; Brundin L
Curr Top Behav Neurosci; 2017; 31():269-284. PubMed ID: 27221623
[TBL] [Abstract][Full Text] [Related]
39. Altered Tryptophan-Kynurenine Pathway in Delirium: A Review of the Current Literature.
Phing AH; Makpol S; Nasaruddin ML; Wan Zaidi WA; Ahmad NS; Embong H
Int J Mol Sci; 2023 Mar; 24(6):. PubMed ID: 36982655
[TBL] [Abstract][Full Text] [Related]
40. The immune effects of TRYCATs (tryptophan catabolites along the IDO pathway): relevance for depression - and other conditions characterized by tryptophan depletion induced by inflammation.
Maes M; Mihaylova I; Ruyter MD; Kubera M; Bosmans E
Neuro Endocrinol Lett; 2007 Dec; 28(6):826-31. PubMed ID: 18063923
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
